Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.63 |
| ▸ | NPC1 | O15118 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.59 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | SNCA | P37840 | 1/20 | 0.51 |
| ▸ | CASP7 | P55210 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698939 | 0.86 | MAPT (0.64) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL9342707 | 0.84 | MAPT (0.63) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL11372271 | 0.84 | MAPT (0.63) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL15478266 | 0.84 | MAPT (0.67) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL29787 | 0.84 | MAPT (0.52) | MAPTNPC1RAB9AKDM4EGAA | |
| SCHEMBL5768391 | 0.84 | MAPT (0.57) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL21681975 | 0.84 | MAPT (0.51) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL28607456 | 0.83 | MAPT (0.61) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| Zinc Ion SCHEMBL5015955 | 0.83 | MAPT (0.61) | MAPTNPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL21682172 | 0.82 | RAB9A (0.47) | MAPTNPC1RAB9AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108299413-A | A method of no metal catalytic prepares 2- (aminocarbonyl phenyl) benzoxazoles and its derivative | 复旦大学 | 2018-07-20 | — | — | CN | disclosed |
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2015-06-04 | — | — | US | disclosed |
| US-8993604-B2 | Treatment and prevention of dengue virus infections | SIGA TECHNOLOGIES, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-10-11 | — | — | US | disclosed |
| EP-1638556-B1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | EP | disclosed |
| US-7297707-B2 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-20070021478-A1 | Benzothiazolyl derivatives | NETTEKOVEN MATTHIAS H | 2007-01-25 | — | — | US | disclosed |
| EP-1638556-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | disclosed |
| WO-2005000301-A1 | 2-AMINOBENZOTHIAZOLES AS CB1 RECEPTOR INVERSE AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-06 | — | — | WO | disclosed |
| US-20040266845-A1 | Benzothiazolyl derivatives | HOFFMANN-LA ROCHE INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150150852-A1 | TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | HAVCR2, TTPA, CHIA | MAPT 118/4885NPC1 672/4885RAB9A 1714/4885 |
| US-20120258079-A1 | Treatment and Prevention of Dengue Virus Infections | HAVCR2, TTPA, CHIA | MAPT 118/4885NPC1 672/4885RAB9A 1714/4885 |
| US-20070021478-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | MAPT 3262/4885NPC1 421/4885RAB9A 1479/4885 |
| US-20040266845-A1 | Benzothiazolyl derivatives | CNR1, CNR2, GPR119 | MAPT 3619/4885NPC1 237/4885RAB9A 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.